Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cory M Johannessen

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
BMC Biology|November 25, 2020
CloneSifter: enrichment of rare clones from heterogeneous cell populationsDavid Feldman, FuNien Tsai, Anthony J Garrity, et al.
Current Biology : CB|January 1, 2008
TORC1 is essential for NF1-associated malignanciesCory M Johannessen, Bryan W Johnson, Sybil M Genther Williams, et al.
Cancer Research|March 2, 2019
A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant MelanomaTikvah K Hayes, Flora Luo, Ofir Cohen, et al.
Nature|November 5, 2013
A melanocyte lineage program confers resistance to MAP kinase pathway inhibitionCory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profilingNikhil Wagle, Caroline Emery, Michael F Berger, et al.
Science Signaling|May 17, 2012
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanomaKris C Wood, David J Konieczkowski, Cory M Johannessen, et al.
Cell Reports|October 21, 2016
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense MutantsLisa Brenan, Aleksandr Andreev, Ofir Cohen, et al.
The Journal of Clinical Investigation|August 23, 2019
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceKatsuhiro Togami, Timothy Pastika, Jason Stephansky, et al.
Nature Chemical Biology|March 25, 2022
Systematic identification of biomarker-driven drug combinations to overcome resistanceMatthew G Rees, Lisa Brenan, Mariana do Carmo, et al.
Cancer Discovery|April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitorsDavid J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
BMC Biology|November 25, 2020
CloneSifter: enrichment of rare clones from heterogeneous cell populationsDavid Feldman, FuNien Tsai, Anthony J Garrity, et al.
Current Biology : CB|January 1, 2008
TORC1 is essential for NF1-associated malignanciesCory M Johannessen, Bryan W Johnson, Sybil M Genther Williams, et al.
Cancer Research|March 2, 2019
A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant MelanomaTikvah K Hayes, Flora Luo, Ofir Cohen, et al.
Nature|November 5, 2013
A melanocyte lineage program confers resistance to MAP kinase pathway inhibitionCory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profilingNikhil Wagle, Caroline Emery, Michael F Berger, et al.
Science Signaling|May 17, 2012
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanomaKris C Wood, David J Konieczkowski, Cory M Johannessen, et al.
Cell Reports|October 21, 2016
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense MutantsLisa Brenan, Aleksandr Andreev, Ofir Cohen, et al.
The Journal of Clinical Investigation|August 23, 2019
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceKatsuhiro Togami, Timothy Pastika, Jason Stephansky, et al.
Nature Chemical Biology|March 25, 2022
Systematic identification of biomarker-driven drug combinations to overcome resistanceMatthew G Rees, Lisa Brenan, Mariana do Carmo, et al.
Cancer Discovery|April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitorsDavid J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.
Pageof 4